Imlygic is an engineered oncolytic virus administered intralesionally; tumor cell killing is achieved by the oncolytic function of the virus, which is engineered to express the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), to recruit and activate innate immune cells, to process TAAs, and that lead to systemic anti-tumor immunity [6]. Here, CSF2 is linked to neoplasm.